uniQure N.V.

About this filing

Item 1. Financial Statements

For the period ended Sep 30, 2026. Filed Nov 4, 2026.

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 4, 2026

QURE$22.79+5.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

· · September 30, · · December 31,

· · 2026 · · 2025

· · (in thousands)

Carrying amount of equity investments

Genezen convertible note receivable

UNAUDITED CONSOLIDATED BALANCE SHEETS


· · September 30, · · December 31,
· · 2026 · · 2025
		(in thousands, except share and per share amounts)
Current assets
Cash and cash equivalents	$98,442		$80,240
Current investment securities	570,021		542,301
Accounts receivable	4,804		5,863
Prepaid expenses	9,601		20,506
Other current assets and receivables	9,677		7,076
Total current assets	692,545		655,986
Non-current assets
Property, plant and equipment, net	9,923		13,800
Other investments	31,539		30,237
Non-current investment securities	99,967		—
Operating lease right-of-use assets	10,980		12,525
Intangible assets, net	61,855		72,790
Goodwill	24,503		25,355
Deferred tax assets, net	5,709		8,654
Other non-current assets	3,530		5,561
Total non-current assets	248,006		168,922
Total assets	$940,551		$824,908
Current liabilities
Accounts payable	$6,173		$5,170
Accrued expenses and other current liabilities	50,979		41,292
Liability related to pre-funded warrants	—		12,595
Current portion of operating lease liabilities	2,990		3,862
Total current liabilities	60,142		62,919
Non-current liabilities
Long-term debt	50,345		49,699
Liability from royalty financing agreement	497,271		473,199
Operating lease liabilities, net of current portion	9,032		9,832
Contingent consideration	18,742		18,736
Deferred tax liability, net	7,699		7,967
Other non-current liabilities, net of current portion	2,667		3,655
Total non-current liabilities	585,756		563,088
Total liabilities	645,898		626,007
Commitments and contingencies
Shareholders' equity
Ordinary shares, €0.05 par value: 100,000,000 shares authorized at September 30, 2026, and 80,000,000 at December 31, 2025, and 70,044,739 and 62,336,717 shares issued and outstanding at September 30, 2026, and December 31, 2025, respectively.	4,128		3,688
Additional paid-in capital	1,874,438		1,582,371
Accumulated other comprehensive loss	(59,166)		(58,222)
Accumulated deficit	(1,524,747)		(1,328,936)
Total shareholders' equity	294,653		198,901
Total liabilities and shareholders' equity	$940,551		$824,908

UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS AND

COMPREHENSIVE LOSS


· · Three months ended September 30, · · Nine months ended September 30,
· · 2026 · · 2025 · · 2026 · · 2025
· · (in thousands, except share and per share amounts) · · (in thousands, except share and per share amounts)
License revenues	$5,196	$3,582	$14,599	$10,411
Collaboration revenues	—	119	—	119
Total revenues	5,196	3,701	14,599	10,530
Operating expenses:
Cost of license revenues	(236)	(398)	(805)	(1,251)
Research and development expenses	(35,517)	(34,366)	(98,657)	(105,889)
Selling, general and administrative expenses	(23,918)	(19,438)	(61,353)	(43,846)
Total operating expenses	(59,671)	(54,202)	(160,815)	(150,986)
Other income	1,690	1,510	4,920	12,413
Other expense	(195)	(2,044)	(9,607)	(6,188)
Loss from operations	(52,980)	(51,035)	(150,903)	(134,231)
Interest income	8,114	3,503	18,394	11,154
Interest expense	(14,576)	(16,721)	(42,973)	(47,421)
Foreign currency (losses) / gains, net	(217)	(428)	(4,241)	25,382
Other non-operating (losses), net	(882)	(7,222)	(13,083)	(7,222)
Loss before income tax expense	$(60,541)	$(71,903)	$(192,806)	$(152,338)
Income tax expense	(676)	(8,626)	(3,005)	(9,547)
Net loss	$(61,217)	$(80,529)	$(195,811)	$(161,885)
Other comprehensive loss:
Foreign currency translation (losses) / gains, net	(915)	158	(944)	(5,945)
Total comprehensive loss	$(62,132)	$(80,371)	$(196,755)	$(167,830)
Loss per ordinary share - basic and diluted
Basic and diluted net loss per ordinary share	$(0.88)	$(1.38)	$(2.95)	$(2.90)
Weighted average shares - basic and diluted	69,900,863	58,516,415	66,322,083	55,880,318

UNAUDITED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY / (DEFICIT)

FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025


· · · · · · · · · Accumulated · · · · ·
· · · · · · · Additional · · other · · · · · Total
· · Ordinary shares · · paid-in · · comprehensive · · Accumulated · · shareholders’
· · No. of shares · · Amount · · capital · · gain / (loss) · · deficit · · equity / (deficit)
· · (in thousands, except share and per share amounts)
Balance at June 30, 2025	54,865,673	$3,250	$1,262,971	$(58,903)	$(1,211,321)	$(4,003)
Loss for the period	—	—	—	—	(80,529)	(80,529)
Other comprehensive gain, net	—	—	—	158	—	158
Follow-on public offering	6,736,841	394	299,832	—	—	300,226
Tax benefit related to historical share issuance	—	—	862	—	—	862
Exercise of share options	532,316	32	8,478	—	—	8,510
Restricted share units distributed during the period	31,070	2	(2)	—	—	—
Share-based compensation expense	—	—	3,522	—	—	3,522
Balance at September 30, 2025	62,165,900	$3,678	$1,575,663	$(58,745)	$(1,291,850)	$228,746

Balance at June 30, 2026	69,334,839	$4,086	$1,841,745	$(58,251)	$(1,463,530)	$324,050
Loss for the period	—	—	—	—	(61,217)	(61,217)
Other comprehensive loss, net	—	—	—	(915)	—	(915)
Exercises of share options	81,875	5	1,404	—	—	1,409
Exercise of pre-funded warrants	526,314	31	25,701	—	—	25,732
Restricted share units distributed during the period	94,282	6	(6)	—	—	—
Issuance of ordinary shares relating to employee stock purchase plan	7,429	—	148	—	—	148
Share-based compensation expense	—	—	5,446	—	—	5,446
Balance at September 30, 2026	70,044,739	$4,128	$1,874,438	$(59,166)	$(1,524,747)	$294,653

UNAUDITED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY / (DEFICIT)

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025


· · · · · · · · · Accumulated · · · · ·
· · · · · · · Additional · · other · · · · · Total
· · Ordinary shares · · paid-in · · comprehensive · · Accumulated · · shareholders’
· · No. of shares · · Amount · · capital · · gain / (loss) · · deficit · · equity / (deficit)
· · (in thousands, except share and per share amounts)
Balance at December 31, 2024	48,988,087	$2,945	$1,173,068	$(52,800)	$(1,129,965)	$(6,752)
Loss for the period	—	—	—	—	(161,885)	(161,885)
Other comprehensive loss, net	—	—	—	(5,945)	—	(5,945)
Follow-on public offerings	11,810,370	655	380,082	—	—	380,737
Tax benefit related to historical share issuance costs	—	—	862	—	—	862
Exercises of share options	553,556	33	8,680	—	—	8,713
Restricted and performance share units distributed during the period	813,887	45	(45)	—	—	—
Share-based compensation expense	—	—	13,016	—	—	13,016
Balance at September 30, 2025	62,165,900	$3,678	$1,575,663	$(58,745)	$(1,291,850)	$228,746

Balance at December 31, 2025	62,336,717	$3,688	$1,582,371	$(58,222)	$(1,328,936)	$198,901
Loss for the period	—	—	—	—	(195,811)	(195,811)
Other comprehensive loss, net	—	—	—	(944)	—	(944)
Follow-on public offering	5,686,813	323	242,359	—	—	242,682
Exercises of share options	492,724	28	8,200	—	—	8,228
Exercise of pre-funded warrants	526,314	31	25,701	—	—	25,732
Restricted share units distributed during the period	980,803	57	(57)	—	—	—
Issuance of ordinary shares relating to employee stock purchase plan	21,368	1	312	—	—	313
Share-based compensation expense	—	—	15,552	—	—	15,552
Balance at September 30, 2026	70,044,739	$4,128	$1,874,438	$(59,166)	$(1,524,747)	$294,653

UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS


· · Nine months ended September 30,
· · 2026 · · 2025
		(in thousands)
Cash flows used in operating activities
Net loss	$(195,811)		$(161,885)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	13,313		11,789
Amortization of discount on investment securities	(13,599)		(6,091)
Share-based compensation expense	15,552		13,016
Royalty financing agreement interest expense, net of interest paid	23,353		29,209
Deferred tax expense	2,945		1,979
Changes in fair value of contingent consideration	616		5,293
Changes in fair value of liability related to pre-funded warrants	13,083		5,722
Unrealized foreign exchange gains / (losses), net	5,123		(24,534)
Other items, net	(3,624)		(3,013)
Changes in operating assets and liabilities:
Accounts receivable, prepaid expenses, and other current assets and receivables	10,124		2,880
Accounts payable	1,279		(1,648)
Income tax payable	5		7,568
Accrued expenses, other liabilities, and operating leases	12,995		19,321
Net cash used in operating activities	(114,646)		(100,394)
Cash flows (used in) / generated from investing activities
Proceeds on maturity of debt securities	466,265		337,195
Investments in debt securities	(582,554)		(217,124)
Purchases of property, plant, and equipment	(623)		(320)
Net cash (used in) / generated from investing activities	(116,912)		119,751
Cash flows from financing activities
Proceeds from follow-on public offering of ordinary shares, net of issuance costs	242,682		380,737
Proceeds from issuance of pre-funded warrants, net of issuance costs	—		23,499
Proceeds from issuance of ordinary shares related to employee stock options and purchase plans	8,541		8,713
Net cash generated from financing activities	251,223		412,949
Currency effect on cash, cash equivalents and restricted cash	(1,494)		5,914
Net increase in cash, cash equivalents and restricted cash	18,171		438,220
Cash, cash equivalents and restricted cash at the beginning of period	81,801		160,329
Cash, cash equivalents and restricted cash at the end of period	$99,972		$598,549
Cash and cash equivalents	$98,442		$597,056
Restricted cash related to leasehold and other deposits	1,530		1,493
Total cash, cash equivalents and restricted cash	$99,972		$598,549
Supplemental cash flow disclosures:
Cash paid for interest	$(18,940)		$(16,659)
Supplemental disclosure of non-cash investing and financing items:
Issuance of ordinary shares upon exercise of pre-funded warrants	$25,732		$—

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1General business information

uniQure N.V. (the “Company”) was incorporated on January 9, 2012, as a private company with limited liability (besloten vennootschap met beperkte aansprakelijkheid) under the laws of the Netherlands. The Company is a leader in the field of gene therapy and seeks to deliver to patients suffering from rare and other devastating diseases single treatments with potentially curative results. The Company’s business was founded in 1998 and was initially operated through its predecessor company, Amsterdam Molecular Therapeutics Holding N.V. (“AMT”). In 2012, AMT undertook a corporate reorganization, pursuant to which uniQure B.V. acquired the entire business and assets of AMT and completed a share-for-share exchange with the shareholders of AMT. Effective February 10, 2014, in connection with its initial public offering, the Company converted into a public company with limited liability (naamloze vennootschap) and changed its legal name from uniQure B.V. to uniQure N.V.

The Company is registered in the trade register of the Dutch Chamber of Commerce (Kamer van Koophandel) in Amsterdam, the Netherlands under number 54385229. The Company’s headquarters are in Amsterdam, the Netherlands, its registered office is located at Paasheuvelweg 25, Amsterdam 1105 BP, the Netherlands and its telephone number is +31 20 240 6000.

The Company’s ordinary shares are listed on the Nasdaq Global Select Market and trade under the symbol “QURE”.

2****Summary of significant accounting policies

2.1****Basis of preparation

The Company prepared these unaudited consolidated financial statements in compliance with generally accepted accounting principles in the United States (“U.S. GAAP”) and applicable rules and regulations of the United States Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. Any reference in these notes to applicable guidance is meant to refer to authoritative U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates of the Financial Accounting Standards Board.

The unaudited consolidated financial statements are presented in United States (“U.S.”) dollars, except where otherwise indicated. Transactions denominated in currencies other than U.S. dollars are presented in the transaction currency with the U.S. dollar amount included in parentheses, converted at the foreign exchange rate as of the transaction date.

2.2****Unaudited interim financial information

The interim financial statements and related disclosures are unaudited, have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the financial position, results of operations and changes in financial position for the period presented.

Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been omitted. The results of operations for thethree and nine months ended September 30, 2026, are not necessarily indicative of the results to be expected for the full year ending December 31, 2026, or for any other future year or interim period. The accompanying financial statements should be read in conjunction with the audited financial statements and the related notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 filed by the Company with the SEC on March 2, 2026 (the “Annual Report”).

2.3****Use of estimates

The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities; the disclosure of contingent liabilities at the date of the financial statements; and the reported amounts of revenues, expenses, and tax-related items during the reporting period. Actual results could differ from those estimates.

2.4****Accounting policies

The principal accounting policies applied in the preparation of these unaudited consolidated financial statements are described in the Company’s audited financial statements as of and for the year ended December 31, 2025, and the notes thereto, which are included in the Annual Report. There have been no material changes in the Company’s significant accounting policies during the nine months ended September 30, 2026.

2.5****Recent accounting pronouncements

There have been no new accounting pronouncements or changes to accounting pronouncements during the nine months ended September 30, 2026, as compared to the recent accounting pronouncements described in Note 2.3.29 of the Annual Report, which could be expected to materially impact the Company’s unaudited consolidated financial statements.

3	Investment securities

The following tables summarize the Company’s investments in government debt securities as of September 30, 2026 and December 31, 2025:


· · September 30, 2026
· · Amortized cost · · Gross unrealized holding gains · · Gross unrealized holding losses · · Estimated fair value
					(in thousands)
Current investments securities:
Government debt securities (held-to-maturity)		$570,021		$—			$(204)	$569,817

Non-current investments securities:
Government debt securities (held-to-maturity)		$99,967		$—			$(1,119)	$98,848
Total		$669,988		$—			$(1,323)	$668,665

	December 31, 2025
	Amortized cost		Gross unrealized holding gains	Gross unrealized holding losses		Estimated fair value
	(in thousands)
Current investments securities:
Government debt securities (held-to-maturity)		$542,301		$308			$—	$542,609
Total		$542,301		$308			$—	$542,609

The Company invests in U.S. and European government debt securities with high investment credit ratings. The U.S. and European government bonds are U.S. dollar and euro (€, or EUR) denominated, respectively. Investment securities with original maturities of 90 days or less when purchased are presented within cash and cash equivalents and measured at amortized cost. Investment securities with contractual maturities greater than 12 months are presented within non-current investment securities and measured at amortized cost. Inputs to the fair value of the investments are considered Level 2 inputs.

As of September 30, 2026 and December 31, 2025, no expected credit loss was identified with respect to the investment securities.

4	Fair value measurement

The Company measures certain financial assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting. ASC 820*, Fair Value Measurement*requires disclosure of the methodologies used in determining the reported fair values and establishes a hierarchy of inputs used when available. The three levels of the fair value hierarchy are described below:

Level 1 – Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company can access at the measurement date.

Level 2 – Valuations based on quoted prices for similar assets or liabilities in markets that are not active or models for which the inputs are observable, either directly or indirectly.

Level 3 – Valuations that require inputs that reflect the Company’s own assumptions that are both significant to the fair value measurement and are unobservable.

To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

The carrying amount of cash and cash equivalents, accounts receivable from licensing and collaboration partners, other assets, accounts payable, accrued expenses and other current liabilities reflected in the Unaudited Consolidated Balance Sheets** **approximate their fair values due to their short-term maturities.

The Company’s material financial assets include cash and cash equivalents, restricted cash, and investment securities. Cash and cash equivalents and restricted cash are measured at fair value using Level 1 inputs. Restricted cash is included in Other non-current assets within the Unaudited Consolidated Balance Sheets. Investment securities are measured at amortized cost.

The following table sets forth the Company’s assets and liabilities that are required to be measured at fair value on a recurring basis as of December 31, 2025 and September 30, 2026:


· · Quoted pricesin activemarkets(Level 1) · · Significant otherobservableinputs(Level 2) · · Significantunobservableinputs(Level 3) · · Total · · Classification in Unaudited ConsolidatedBalance Sheets
· · · (in thousands) · ·
Balance at December 31, 2025
Assets:
Cash and cash equivalents	$80,240	$—	$—	$80,240	Cash and cash equivalents
Restricted cash	1,561	—	—	1,561	Other non-current assets
Total assets	$81,801	$—	$—	$81,801
Liabilities:
Liability related to pre-funded warrants	—	12,595	—	12,595	Liability related to pre-funded warrants
Contingent consideration	—	—	18,736	18,736	Contingent consideration
Consideration for post-acquisition services	—	—	638	638	Other non-current liabilities
Total liabilities	$—	$12,595	$19,374	$31,969
Balance at September 30, 2026
Assets:
Cash and cash equivalents	$98,442	$—	$—	$98,442	Cash and cash equivalents
Restricted cash	1,530	—	—	1,530	Other non-current assets
Total assets	$99,972	$—	$—	$99,972
Liabilities:
Contingent consideration	—	—	18,742	18,742	Contingent consideration
Consideration for post-acquisition services	—	—	638	638	Other non-current liabilities
Total liabilities	$—	$—	$19,380	$19,380

a)	Contingent consideration

The Company is required to pay up to EUR 143.1 million (or $162.4 million based on the foreign exchange rate on September 30, 2026) to the former shareholders of uniQure France SAS (formerly Corlieve Therapeutics SAS) upon the achievement of the remaining contractually defined milestones related to the development of AMT-260 in connection with the Company’s acquisition of uniQure France SAS.

The fair value of the contingent consideration as of September 30, 2026 was EUR 16.5 million ($18.7 million) (December 31, 2025: EUR 15.9 million ($18.7 million)) using discount rates of approximately 9.7% to 11.8% (December 31, 2025:11.8%).

If, as of September 30, 2026, the Company had assumed a 100% likelihood of AMT-260 advancing into a Phase III clinical study, then the fair value of the contingent consideration would have increased to EUR 53.2 million ($60.4 million). If, as of September 30, 2026, the Company had assumed that it would discontinue development of the AMT-260 program, then the contingent consideration would have been released to income.

The following table presents the changes in fair value of the contingent consideration (presented within non-current liabilities) between December 31, 2025 and September 30, 2026:


· · Amount of
· · contingent
· · consideration
· · (in thousands)
Balance at December 31, 2025			$18,736
Unrealized change in fair value (presented within Research and development expenses)			616
Currency translation effects			(610)
Balance at September 30, 2026			$18,742

The Company classified the total contingent consideration liability as non-current as of September 30, 2026 and December 31, 2025. The classification of the contingent consideration within the Company’s Unaudited Consolidated Balance Sheets between current and non-current liabilities is based upon the Company’s best estimate of the timing of settlement of the remaining relevant milestones.

b)	Liability related to pre-funded warrants

In connection with its September 2025 follow-on public offering, the Company issued pre-funded warrants to purchase 526,316 ordinary shares at a price per warrant equal to the public offering price of $47.50 per ordinary share less the $0.0001 per share exercise price ("Pre-Funded Warrants"). The obligation to issue ordinary shares upon exercise was classified as a liability and measured at fair value using a valuation technique whose significant inputs were observable; the fair value measurement was therefore classified within Level 2 of the fair value hierarchy.

In August 2026, the holder exercised all outstanding Pre-Funded Warrants, and the Company issued ordinary shares from its reserve account. Immediately prior to exercise, the liability was remeasured to fair value, and its carrying amount was classified to shareholders' equity upon issuance of the ordinary shares (refer to Note 8, "Shareholders' equity").


· · Liability related
· · to pre-funded
· · warrants
· · (in thousands)
Balance at December 31, 2025			$12,595
Realized increase in fair value (presented within Other non-operating (losses), net)			13,083
Currency translation effects			54
Settlement of pre-funded warrant liability through issuance of ordinary shares			(25,732)
Balance at September 30, 2026			$—

5	Accrued expenses and other current liabilities

Accrued expenses and other current liabilities consisted of the following items as of September 30, 2026 and December 31, 2025:


· · September 30, · · December 31,
· · 2026 · · 2025
· · (in thousands)
Accruals for goods received from and services provided by vendors, not yet billed	$26,997	$20,490
Personnel-related accruals and liabilities	15,139	9,941
Liability owed to the Purchaser pursuant to the Royalty Financing Agreement (refer to Note 7, "Royalty Financing Agreement")	4,804	5,523
Current portion of firm purchase commitment liability and Genezen CSA termination payment	3,808	5,102
Other current liabilities	231	236
Total	$50,979	$41,292

In April 2026, the Company entered into an agreement to terminate the commercial supply agreement (the “Genezen CSA”) with Genezen MA, Inc. (together with Genezen Holdings Inc., “Genezen”). Pursuant to the termination agreement, the Company’s obligation to supply HEMGENIX® and any minimum purchase commitments under the Genezen CSA terminated.

6****Long-term debt

In July 2026, the Company entered into an amendment to its venture debt loan facility with Hercules Capital, Inc. (as amended, the "2026 Amended Facility"). The amendment extended the period during which the Company may draw the $100.0 million term loan tranche from June 15, 2027 to September 30, 2027. Except as provided for in the amendment, the terms of borrowing under the 2026 Amended Facility remained unchanged.

The total principal outstanding under the 2026 Amended Facility as of September 30, 2026 was $50.0 million. The amortized cost was $50.7 million as of September 30, 2026 (including $0.4 million of interest due presented within Accrued expenses and other current liabilities), compared to $50.1 million as of December 31, 2025, and is recorded net of discount and debt issuance costs.

The foreign currency loss on the 2026 Amended Facility in the three and nine months ended September 30, 2026 was $0.2 million and $1.8 million, respectively, compared to a foreign currency gain of $2.8 million and $9.2 million, respectively, during the same periods in 2025. Interest expense during the three and nine months ended September 30, 2026 was $1.4 million and $4.2 million, respectively, compared to $1.8 million and $5.4 million, respectively, during the same periods in 2025.

During the nine months ended September 30, 2026, the covenants under the 2026 Amended Facility were amended to include a new United Kingdom entity. Other than this amendment and as described above, there were no material changes to the terms, available borrowing tranches, covenants, or collateral arrangements of the 2026 Amended Facility as described in Note 11, "Long-term debt," to the consolidated financial statements included in the Annual Report. As of September 30, 2026, the Company was in compliance with all applicable covenants under the 2026 Amended Facility.

7Royalty Financing Agreement

During the nine months ended September 30, 2026, there were no material changes to the terms of the royalty purchase agreement entered into in May 2023 (the “Royalty Financing Agreement”) with HemB SPV, L.P. (the “Purchaser”), as described in Note 12, “Royalty Financing Agreement” within the consolidated financial statements included in the Annual Report.

The following table presents the changes in the liability from the Royalty Financing Agreement for the period from December 31, 2025 to September 30, 2026:


· · Amount of liability
· · (in thousands)
Balance as of December 31, 2025 (includes $5.5 million presented as "Accrued expenses and other current liabilities")			$478,722
Royalty payments to the Purchaser			(15,395)
Interest expense for the period			38,748
Balance as of September 30, 2026 (includes $4.8 million presented as "Accrued expenses and other current liabilities")			$502,075

The Company records the debt at amortized cost using the effective interest method based on projected cash flows. As of September 30, 2026, the effective interest rate is expected to be within a range of 10.0% to 11.5% per annum (September 30, 2025:10.5% to 12.0%). Interest expense recorded in connection with the Royalty Financing Agreement was $13.2 million and $13.8 million for the three months ended September 30, 2026 and 2025, respectively, and $38.7 million and $40.9 million for the nine months ended September 30, 2026 and 2025, respectively.

8Shareholders’ equity

In June 2026, the Company received net proceeds of$242.7 million, after deducting underwriting discounts and commissions and other offering expenses payable by the Company, through a follow-on public offering of 5.7 million ordinary shares, at a public offering price of$45.50 per ordinary share.

In June 2026, the Company's shareholders approved an amendment to the Articles of Association increasing the Company's authorized share capital from 80.0 million ordinary shares to 100.0 million ordinary shares with a nominal value of €0.05 per share.

In August 2026, all outstanding Pre-Funded Warrants were exercised by the holder, and the Company issued 526,314 ordinary shares from its reserve account. Upon exercise, the fair value of the liability related to Pre-Funded Warrants of EUR 22.0 million ($25.7 million) was reclassified to shareholders' equity.

9Share-based compensation

The Company’s share-based compensation plans include the amended and restated 2014 Share Incentive Plan (as amended, the “2014 Plan”) and inducement grants under Rule 5653(c)(4) of the Nasdaq Global Select Market with terms similar to the 2014 Plan (together the “2014 Plans”). As of September 30, 2026, a total of 2,698,090 ordinary shares remain available for issuance under the 2014 Plan.

In June 2018, the Company’s shareholders adopted and approved the uniQure N.V. Employee Stock Purchase Plan (as amended, the “ESPP”) allowing the Company to issue up to 150,000 ordinary shares. The ESPP is intended to qualify under Section 423 of the Internal Revenue Code of 1986, as amended. Under the ESPP, employees are eligible to purchase ordinary shares through payroll deductions, subject to any plan limitations. The purchase price of the ordinary shares on each purchase date is equal to the lower of: (i)85% of the closing market price on the offering date or (ii)85% of the closing market price on the purchase date.

2014 Plans and ESPP

Share-based compensation expense recognized by classification included in the Unaudited Consolidated Statements of Operations and Comprehensive Loss in relation to the 2014 Plans and the ESPP for the periods indicated below was as follows:


· · Three months ended September 30, · · Nine months ended September 30,
· · 2026 · · 2025 · · 2026 · · 2025
· · (in thousands) · · (in thousands)
Research and development expenses	2,081	695	5,946	5,916
Selling, general and administrative expenses	3,365	2,827	9,606	7,100
Total	$5,446	$3,522	$15,552	$13,016

Share-based compensation expense recognized by award type for the 2014 Plans as well as the ESPP was as follows:


· · Three months ended September 30, · · Nine months ended September 30,
· · 2026 · · 2025 · · 2026 · · 2025
		(in thousands)			(in thousands)
Award type/ESPP
Share options	$1,941		$1,829	$5,609		$5,128
Restricted share units	3,365		2,837	9,826		7,597
Performance share units	124		(1,159)	78		276
ESPP	16		15	39		15
Total	$5,446		$3,522	$15,552		$13,016

As of September 30, 2026, the unrecognized share-based compensation expense related to unvested awards under the 2014 Plans was:


· · Unrecognized · · Weighted average
· · share-based · · remaining
· · compensation · · period for
· · expense · · recognition
· · (in thousands) · · (in years)
Award type
Share options	$13,097	2.49
Restricted share units	28,354	2.18
Performance share units	302	0.61
Total	$41,753	2.27

The Company satisfies the exercise of share options and vesting of Restricted Share Units (“RSUs”) and Performance Share Units (“PSUs”) through newly issued ordinary shares.

Share options

Share options are priced on the date of grant and, except for certain grants made to non-executive directors, vest over a period offour years. The first 25% of each grant vestsone year after the initial grant date and the remainder vests in equal quarterly installments over years two, three and four. Certain grants to non-executive directors vest in full afterone year. Any options that vest must be exercised by the tenth anniversary of the initial grant date.

The following table summarizes option activity under the 2014 Plans for the nine months ended September 30, 2026:


· · Options
	Number of ordinary shares	Weighted average exercise price

Outstanding at December 31, 2025	4,531,991	17.04
Granted	889,760	$12.18
Forfeited	(13,951)	$9.53
Expired	(16,186)	$37.84
Exercised	(492,724)	$16.70
Outstanding at September 30, 2026	4,898,890	$16.14
Thereof, fully vested, and exercisable on September 30, 2026	2,874,645	$19.36
Thereof, outstanding and expected to vest after September 30, 2026	2,024,245	$11.58
Outstanding and expected to vest after December 31, 2025	1,999,315	$11.81

· · · · ·
Total weighted average grant date fair value of options issued during the period (in $ millions)				$7.0

The fair value of each option issued is estimated at the respective grant date using the Hull & White option pricing model with the following weighted-average assumptions:


· · Three months ended September 30, · · Nine months ended September 30,
	2026	2025	2026	2025
Assumptions
Expected volatility	100%	80%	95% - 100%	70% - 80%
Expected terms	10 years	10 years	10 years	10 years
Risk-free interest rate	5.23%	4.38%	4.21% - 5.23%	4.36% - 4.64%
Expected dividend yield	0.0%	0.0%	0.0%	0.0%

RSUs

The following table summarizes the RSU activity for the nine months ended September 30, 2026:


· · RSUs
· · · · Weighted average
· · Number of · · grant-date fair
· · ordinary shares · · value
Non-vested at December 31, 2025	2,395,420	$12.15
Granted	1,254,450	$15.81
Vested	(980,803)	$12.25
Forfeited	(134,012)	$15.56
Non-vested at September 30, 2026	2,535,055	$13.74

Total weighted average grant date fair value of RSUs granted during the period (in $ millions)		$19.8

RSUs are measured at grant date based on the market price of the Company’s ordinary shares and, except for certain grants made to non-executive directors, vest over athree-year period. RSUs granted to non-executive directors vestone year after the date of grant.

PSUs

The Company has granted PSUs to certain employees of the Company that represent shares potentially issuable in the future. The 2026 PSUs will be earned upon Company management's assessment of the level of achievement of agreed upon performance targets, subject to the grantee's continued employment.

The fair value of PSUs is determined on the grant date by reference to the market price of the Company's ordinary shares, and the Company recognizes the related compensation cost to the extent it considers achievement of the milestones to be probable.

As of September 30, 2026, certain 2026 PSUs were assessed as probable of achieving the requisite performance condition. During the nine months ended September 30, 2026, the performance target applicable to the 2024 PSUs was not met within the contractually defined performance period and the outstanding 2024 PSUs were forfeited.

The following table summarizes the PSU activity for the nine months ended September 30, 2026:

· · · · ·
· · PSUs
		Weighted average
	Number of	grant-date fair
	ordinary shares	value
Non-vested at December 31, 2025	22,500	$15.40
Granted	28,750	$22.40
Vested	—	$—
Forfeited	(22,500)	$15.40
Non-vested at September 30, 2026	28,750	$22.40

ESPP

During the nine months ended September 30, 2026,21,368 ordinary shares were issued under the ESPP compared tonil ordinary shares issued during the same period in 2025. As of September 30, 2026,65,344 ordinary shares remain available for issuance under the ESPP compared to a total of 86,712 ordinary shares as of September 30, 2025.

10	Segment reporting

The Company is advancing a pipeline of innovative gene therapies seeking to deliver to patients suffering from rare and other devastating diseases single treatments with potentially curative results. The Company manages the operations related to these research and development activities withinone operating segment because they rely on a common set of infrastructure, resources and technology of the products and production processes, types of customers, distribution methods and regulatory environment.

The leadership team is identified as the Chief Operating Decision Maker (“CODM”).

The CODM allocates resources to research projects and clinical candidates based on scientific data as well as quantitative and qualitative expected risk-adjusted returns on investment. The CODM uses segment operating loss to monitor that cash operating losses remain within the approved budget.

The accounting policies of the operating segment are the same as those described in the summary of significant accounting policies.


· · Three months ended September 30, · · Nine months ended September 30,
· · 2026 · · 2025 · · 2026 · · 2025
· · (in thousands) · · (in thousands)
Revenue	$5,196	$3,701	$14,599	$10,530
Less:
Employee related expenses	(17,271)	(14,666)	(51,017)	(43,407)
Laboratory and development expenses	(17,174)	(18,675)	(49,322)	(50,235)
Professional fees	(7,865)	(4,814)	(14,128)	(9,995)
Information technology system costs(2)	(1,599)	(952)	(4,685)	(2,791)
Facility expenses	(1,710)	(1,677)	(4,694)	(5,048)
Other segment items(1) (2)	(3,039)	(2,217)	(9,063)	(4,990)
Segment operating loss	(43,462)	(39,300)	(118,310)	(105,936)
Reconciliation
Depreciation and amortization expense	(1,481)	(3,632)	(9,344)	(11,789)
Share-based compensation expense	(5,446)	(3,522)	(15,552)	(13,016)
Fair value (loss) / gain - contingent consideration	(698)	(1,823)	(616)	(5,293)
Fair value loss - Liability related to pre-funded warrants	(882)	(5,722)	(13,083)	(5,722)
Foreign currency (losses) / gains, net	(217)	(428)	(4,241)	25,382
Interest income	8,114	3,503	18,394	11,154
Interest expense - Royalty Financing Agreement	(13,164)	(13,806)	(38,748)	(40,885)
Interest expense - Hercules loan facility	(1,406)	(1,794)	(4,219)	(5,415)
Other reconciling items	(1,899)	(5,379)	(7,087)	(818)
Consolidated loss before income tax expense	$(60,541)	$(71,903)	$(192,806)	$(152,338)

(1)	Other segment items included in segment operating loss include costs related to intellectual property and insurance offset by income related to payments received from European authorities to subsidize the Company’s research and development in the Netherlands.

(2)

The comparative amounts for the three and nine months ended September 30, 2025 have been adjusted to reflect the level of detail at which the CODM reviews segment operating expenses in 2026, with information technology system costs presented as a separate line item and consumables included within other segment items for all periods presented.

11	Other investments and concentration of credit risk

The following table summarizes the Company’s Other investments as of September 30, 2026 and December 31, 2025:

Carrying amount of equity investments

The Company holds investments in non-publicly traded equity securities without readily determinable fair values. These investments are accounted for at cost, less impairment and adjusted to fair value if there are observable price changes in orderly transactions for identical or similar investments using the measurement alternative in accordance with ASC 321,Investments – Equity Securities.

The carrying value of these investments as of September 30, 2026 and December 31, 2025 was $15.1 million and $15.6 million, respectively, and is presented within Other investments in the Company’s Unaudited Consolidated Balance Sheets. The Company did not recognize any upward adjustments, downward adjustments, or impairments relating to investments carried under the measurement alternative during the three and nine months ended September 30, 2026, and 2025.

Genezen

The Company held a convertible promissory note issued in July 2024 by Genezen at a nominal amount of $12.5 million, maturing in October 2029 (the "Original Note"). The original note’s nominal interest of 8.0% per annum was payable in kind and is added to the principal at the end of each quarter. The nominal amount as well as the accumulated interest were convertible into Genezen’s common stock at $2.20 per share.

On August 11, 2026, in connection with the refinancing of Genezen’s senior credit facilities, the Original Note was amended and restated (the "Amended Note"). The Amended Note has a contractually agreed principal amount of $15.1 million and matures in December 2031. The Amended Note bears nominal interest at 15.0% per annum, payable in kind, and is added to the principal at the end of each quarter. The nominal amount as well as 8.0% of the total 15.0% interest per annum are convertible into Genezen’s common stock at the lesser of $2.20 and the lowest price per share of Genezen’s common stock issued in an equity issuance consummated while the Amended Note is outstanding.

The amendment was accounted for as a continuation of the Original Note under ASC 310 and did not result in the recognition of a new loan. As a result, the Company's investment in the Amended Note was recorded based on the remaining net investment in the Original Note immediately prior to the amendment. The Amended Note had an amortized cost basis of $16.4 million as of September 30, 2026 (December 31, 2025: $14.6 million) and is presented within Other investments. No material allowance for expected credit losses was recognized as of September 30, 2026.

CSL Behring

As of September 30, 2026, and December 31, 2025, accounts receivable from CSL Behring LLC ("CSL Behring") totaled$4.8 million and$5.9 million, respectively, in each case related to royalty revenue which is included in License Revenues in the accompanying Unaudited Consolidated Statements of Operations and Comprehensive Loss.

12	Income taxes

The Company recorded a deferred tax expense of$0.6 million and$2.9 million related to its U.S. operations during the three and nine months ended September 30, 2026 ($0.2 million and$1.1 million for the three and nine

months ended September 30, 2025). In addition, during the three and nine months ended September 30, 2025, the Company recorded$7.5 million of current income tax expense and$0.9 million of deferred income tax expense related to its Dutch operations as a result of a revised assessment of the Dutch corporate income tax treatment of the$375.0 million upfront payment received in 2023 under the Royalty Financing Agreement.

The effective income tax rate of 1.1% and 1.6% during the three and nine months ended September 30, 2026 (three and nine months ended September 30, 2025:12.0% and 6.3%, respectively) is substantially lower than the enacted rate of 25.8% in the Netherlands as the Company recorded a valuation allowance against its net deferred tax assets in the Netherlands and a partial valuation allowance against its net deferred tax assets in France, among various other items which impacted the effective rate.

13****Basic and diluted loss per share

Diluted loss per ordinary share is calculated by adjusting the weighted average number of ordinary shares outstanding, assuming conversion of all potentially dilutive ordinary shares. As the Company incurred a loss in the three and nine months ended September 30, 2026, all potentially dilutive ordinary shares would have an antidilutive effect, if converted, and thus have been excluded from the computation of diluted loss per share for the three and nine months ended September 30, 2026. The ordinary shares are presented without giving effect to the application of the treasury method or exercise prices that would be above the share price as of September 30, 2026 and September 30, 2025, respectively.

The potentially dilutive ordinary shares are summarized below:


· Three months ended September 30, · · Nine months ended September 30,
	2026	2025	2026	2025
Anti-dilutive ordinary share equivalents
Share options under 2014 Plans	$4,898,890	4,682,032	$4,898,890	4,682,032
Non-vested RSUs and PSUs	2,563,805	2,332,353	2,563,805	2,332,353
Pre-Funded Warrants	—	526,316	—	526,316
ESPP	21,368	7,239	21,368	7,239
Total anti-dilutive ordinary share equivalents	7,484,063	7,547,940	7,484,063	7,547,940

The Pre-Funded Warrants were fully exercised in August 2026 (refer to Note 4, "Fair value measurement").

14Commitments and contingencies

In the course of its business, the Company enters as a licensee into contracts with other parties regarding the development and marketing of certain of its pipeline products. Among other payment obligations, the Company is obligated to pay royalties to the licensors based on future sales levels and milestone payments whenever specified development, regulatory and commercial milestones are met. As both future sales levels and the timing and achievement of milestones are uncertain, the financial effect of these agreements cannot be reliably estimated. The Company also has obligations to make future payments that become due and payable upon the collection of milestone payments from CSL Behring. The achievement and timing of these milestones are not fixed or determinable.

Legal Proceedings

On February 10, 2026, a class action complaint captionedChristopher Scocco v. uniQure N.V., et al., Case No. 1:26-cv-01124, was filed against the Company, certain of its executive officers and another party (collectively, “Defendants”) in the United States District Court for the Southern District of New York. The complaint purported to assert claims pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Rule 10b-5 promulgated thereunder, on behalf of a putative class of investors who purchased or otherwise acquired the Company’s ordinary shares between September 24, 2025 and October 31, 2025 (the “putative Class Period”). The plaintiff sought to recover damages allegedly caused by purported false and misleading statements and omissions with respect to the Company’s Phase I/II study of ifezuntirgene inilparvovec and the timing of the potential Biologics License Application filing for ifezuntirgene inilparvovec.

On April 13, 2026, the court appointed the Oklahoma Firefighters Pension and Retirement System as lead plaintiff (the “Lead Plaintiff”).

On July 15, 2026, the Lead Plaintiff filed an amended complaint. Like the earlier-filed complaint, the amended complaint purports to assert claims pursuant to Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5, on behalf of a putative class of investors who purchased or otherwise acquired the Company’s ordinary shares during the putative Class Period. Lead Plaintiff seeks unspecified damages allegedly caused by purported false and misleading statements and omissions with respect to the import and viability of data from the Company’s Phase I/II study of ifezuntirgene inilparvovec and available pathways to regulatory approval. Defendants’ motion to dismiss the amended complaint is currently due November 4, 2026. Management intends to vigorously defend against the claims in this action.

At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company has not recorded any liability for any portion of this matter because the Company believes that liability is not probable and reasonably estimable at this time.

15Subsequent events

None.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.